Developer docs
API playgroundTry for free, no card

Search company profiles

Accelmed

Full company profile

uuid0000e6y

Namestring
Accelmed
Legal namestring
Accelmed Partners
Websiteurl
accelmed.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Accelmed Partners is a private equity firm founded in 2009 by Dr. Uri Geiger with backing from Israeli healthcare entrepreneur Mori Arkin, originally operating as Accelmed Ventures (a $100M early-stage vehicle) before pivoting to a commercial-stage HealthTech buyout strategy with the launch of Accelmed Fund I, LP in 2016. The firm invests exclusively in U.S. commercial-stage lower-middle-market HealthTech companies with $20M-$70M revenues (control) or $10M+ (growth), deploying $20-100M+ per transaction across medical devices, tools & diagnostics, digital health, and tech-enabled healthcare services. Accelmed currently manages over $630 million of equity capital across two private equity funds, with Fund II closing at a $400 million hard cap in 2021 (more than 3x Fund I's $130M). The firm's revenue model is standard for private equity: recurring management fees on committed/invested capital plus performance-based carried interest (typically 20%) from successful exits, with the firm historically generating a 26.4% net IRR on Fund I (top quartile per PitchBook).

The firm operates a buy-and-build platform strategy, working closely with portfolio company management to improve operations, update product portfolios, and revamp commercial organizations, while executing add-on acquisitions to scale platform companies (e.g., Keystone Dental acquiring Osteon Medical; Veranex acquiring Medidee and Fusion Biotec; Bioness Medical acquiring Harmonic Bionics and the PoNS System). Accelmed sources deals through direct outreach and industry relationships, leveraging its Israeli roots for proprietary deal flow into U.S. markets, and exits via strategic acquisitions (Cogentix to Laborie for $240M, CartiHeal to Smith & Nephew for up to $330M, Trukera Medical to Bausch + Lomb) and SPAC mergers (Memic at over $1B equity value). The investment team of approximately 10-15 professionals combines PE transaction expertise with deep operating talent, including former Medtronic and FDA regulatory leadership, enabling active technical support across the portfolio.

Short descriptiontext

Accelmed Partners is a private equity firm founded in 2009 that invests $20-100M+ in U.S. commercial-stage lower-middle-market HealthTech companies across medical devices, diagnostics, digital health, and tech-enabled services, managing over $630 million across two funds from offices in Aventura and Miami, Florida.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMiami, United States
HQ citystring
Miami
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare private equity, HealthTech investing, medical device investments, growth capital, digital health funding
Industry1 code
PRIMARYFSANACAL
Education / EdTech Growth Equity
NAICS code3 codes
  • Portfolio Management and Investment Advice523940
  • Open-End Investment Funds525910
  • Funds, Trusts, and Other Financial Vehicles525
SIC code2 codes
  • Services-Management Consulting Services8742
  • Investment Advice6282
Product category
Healthcare Private Equity
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Management Fees
TypeSubscription Recurring
Description

Private equity fund management fees charged on committed capital to cover operational costs and fund management.

accelmed.com
2Carried Interest
TypeTransaction Fee
Description

Performance-based carried interest from successful portfolio company exits, typically 20% of profits above hurdle rate.

accelmed.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Accelmed is a private equity firm that makes control and growth investments in U.S. commercial-stage lower middle market HealthTech companies with revenues of $20-70M (control) or $10M+ (growth). The firm manages over $630 million across two private equity funds (Fund I at $130M and Fund II at $400M) plus the earlier $100M Accelmed Ventures vehicle, deploying $20-100M+ per company in medical devices, diagnostics, digital health, and tech-enabled services, and working closely with management teams on operational improvements and buy-and-build strategies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 26.4% net IRR for Fund I (top quartile performance)
+4 more records
Product overview1 text field

Accelmed is a private equity firm focused on acquiring and investing in commercial-stage HealthTech companies. The firm manages over $630 million across two private equity funds and maintains a portfolio of approximately 21 active portfolio companies spanning medical devices, tools & diagnostics, digital health, and tech-enabled services. Accelmed's portfolio includes notable companies such as Click Therapeutics (prescription digital therapeutics including CT-155 for schizophrenia, CT-132 for migraine, and Rejoyn for depression), Bioness Medical (advanced neuro rehabilitation technologies including FES systems and PoNS neuromodulation), GT Medical Technologies (GammaTile radiation therapy), NeuroPace (RNS System for epilepsy), MedMinder (connected pharmacy care), Acclaro Medical (aesthetic laser technology), Veranex (MedTech product development services), SKNV (dermatology digital health), Keystone Dental (dental implants), and AiCure (AI patient monitoring). The firm employs a private equity approach to health technology investing, working closely with management to improve operations, update product portfolios, and revamp commercial organizations.

Product and service4 records
1Accelmed Fund I, LP
CategoryPrivate Equity Fund
2Accelmed Fund II, LP
CategoryPrivate Equity Fund
3Accelmed Ventures
CategoryVenture Capital Fund
4Control and Growth Capital Investments
CategoryInvestment Services
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Boehringer Ingelheim
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-09
Description

Pharmaceutical partner in Click Therapeutics' prescription digital therapeutic CT-155 for schizophrenia. Boehringer made $50M Series D strategic investment and transferred commercialization rights to Click. Ongoing collaboration on ENSPIRUS study completion.

accelmed.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Healthcare-focused PE firm with ~$400M committed capital that co-led Accelmed's investment in Click Therapeutics. Directly comparable as a HealthTech-dedicated growth equity and buyout sponsor operating in similar deal-size band.

TypeDirect peer
Description

HealthTech-focused investment firm based in Paris and San Francisco with a €260M vehicle that co-invested with Accelmed in Veranex. Closely comparable as a transatlantic HealthTech PE sponsor with similar sector focus.

TypeDirect peer
Description

Healthcare-dedicated growth equity firm investing in commercial-stage medical device, biotech, and digital health companies. Comparable to Accelmed in sector focus, stage (commercial/growth), and transaction sizes.

TypeDirect peer
Description

Healthcare-focused PE firm making control and growth investments across medical devices, services, and pharmaceuticals. Comparable as a HealthTech-dedicated sponsor with a buy-and-build orientation similar to Accelmed.

TypeDirect peer
Description

Healthcare-focused PE firm investing in middle-market medical device, pharmaceutical, and healthcare services companies. Comparable to Accelmed in sector specialization and middle-market deal-size focus.

TypeDirect peer
Description

Healthcare-dedicated PE firm investing in middle-market companies across medical devices, specialty pharma, and services. Comparable to Accelmed in sector focus and lower middle market deal profile.

TypeDirect peer
Description

European healthcare and life sciences specialist with growth and venture capital strategies. Comparable to Accelmed in HealthTech sector focus though typically investing at earlier stages and primarily in European assets.

TypeRegional player
Description

European healthcare specialist investing across medical devices, digital health, and therapeutics. Comparable to Accelmed in healthcare specialization but primarily serves European companies rather than the US lower middle market.

TypeDirect peer
Description

Healthcare-dedicated growth equity firm with US and Middle East operations. Comparable to Accelmed in healthcare specialization and growth-stage focus, with complementary geographic reach.

TypeDirect peer
Description

Middle-market PE firm specializing in healthcare and life sciences. Comparable to Accelmed in healthcare-dedicated middle-market deal profile and growth equity orientation.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment45 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Accelmed

Healthcare Private Equityaccelmed.com

Accelmed Partners is a private equity firm founded in 2009 that invests $20-100M+ in U.S. commercial-stage lower-middle-market HealthTech companies across medical devices, diagnostics, digital health, and tech-enabled services, managing over $630 million across two funds from offices in Aventura and Miami, Florida.

What Accelmed does

Accelmed Partners is a private equity firm founded in 2009 by Dr. Uri Geiger with backing from Israeli healthcare entrepreneur Mori Arkin, originally operating as Accelmed Ventures (a $100M early-stage vehicle) before pivoting to a commercial-stage HealthTech buyout strategy with the launch of Accelmed Fund I, LP in 2016. The firm invests exclusively in U.S. commercial-stage lower-middle-market HealthTech companies with $20M-$70M revenues (control) or $10M+ (growth), deploying $20-100M+ per transaction across medical devices, tools & diagnostics, digital health, and tech-enabled healthcare services. Accelmed currently manages over $630 million of equity capital across two private equity funds, with Fund II closing at a $400 million hard cap in 2021 (more than 3x Fund I's $130M). The firm's revenue model is standard for private equity: recurring management fees on committed/invested capital plus performance-based carried interest (typically 20%) from successful exits, with the firm historically generating a 26.4% net IRR on Fund I (top quartile per PitchBook).

The firm operates a buy-and-build platform strategy, working closely with portfolio company management to improve operations, update product portfolios, and revamp commercial organizations, while executing add-on acquisitions to scale platform companies (e.g., Keystone Dental acquiring Osteon Medical; Veranex acquiring Medidee and Fusion Biotec; Bioness Medical acquiring Harmonic Bionics and the PoNS System). Accelmed sources deals through direct outreach and industry relationships, leveraging its Israeli roots for proprietary deal flow into U.S. markets, and exits via strategic acquisitions (Cogentix to Laborie for $240M, CartiHeal to Smith & Nephew for up to $330M, Trukera Medical to Bausch + Lomb) and SPAC mergers (Memic at over $1B equity value). The investment team of approximately 10-15 professionals combines PE transaction expertise with deep operating talent, including former Medtronic and FDA regulatory leadership, enabling active technical support across the portfolio.

Accelmed firmographics

Firmographics
Name
Accelmed
Legal name
Accelmed Partners
Website
https://accelmed.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
1–10 employees
Short description
Accelmed Partners is a private equity firm founded in 2009 that invests $20-100M+ in U.S. commercial-stage lower-middle-market HealthTech companies across medical devices, diagnostics, digital health, and tech-enabled services, managing over $630 million across two funds from offices in Aventura and Miami, Florida.
Ownership category
akta.pro rank

Accelmed industry classification

Industry
Product category
Healthcare Private Equity
NAICS
Portfolio Management and Investment Advice (523940), Open-End Investment Funds (525910), Funds, Trusts, and Other Financial Vehicles (525)
SIC
Services-Management Consulting Services (8742), Investment Advice (6282)
akta.pro industry
PRIMARYFSANACAL
Education / EdTech Growth Equity

Keywords

  • Healthcare private equity
  • HealthTech investing
  • Medical device investments
  • Growth capital
  • Digital health funding

Where Accelmed is headquartered

Location

Headquarters

HQ city
Miami
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Accelmed business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Management Fees: Private equity fund management fees charged on committed capital to cover operational costs and fund management.
  2. Carried Interest: Performance-based carried interest from successful portfolio company exits, typically 20% of profits above hurdle rate.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Accelmed product offering

Product offering

Core offering

Accelmed is a private equity firm that makes control and growth investments in U.S. commercial-stage lower middle market HealthTech companies with revenues of $20-70M (control) or $10M+ (growth). The firm manages over $630 million across two private equity funds (Fund I at $130M and Fund II at $400M) plus the earlier $100M Accelmed Ventures vehicle, deploying $20-100M+ per company in medical devices, diagnostics, digital health, and tech-enabled services, and working closely with management teams on operational improvements and buy-and-build strategies.

Product overview

Accelmed is a private equity firm focused on acquiring and investing in commercial-stage HealthTech companies. The firm manages over $630 million across two private equity funds and maintains a portfolio of approximately 21 active portfolio companies spanning medical devices, tools & diagnostics, digital health, and tech-enabled services. Accelmed's portfolio includes notable companies such as Click Therapeutics (prescription digital therapeutics including CT-155 for schizophrenia, CT-132 for migraine, and Rejoyn for depression), Bioness Medical (advanced neuro rehabilitation technologies including FES systems and PoNS neuromodulation), GT Medical Technologies (GammaTile radiation therapy), NeuroPace (RNS System for epilepsy), MedMinder (connected pharmacy care), Acclaro Medical (aesthetic laser technology), Veranex (MedTech product development services), SKNV (dermatology digital health), Keystone Dental (dental implants), and AiCure (AI patient monitoring). The firm employs a private equity approach to health technology investing, working closely with management to improve operations, update product portfolios, and revamp commercial organizations.

Differentiator

Problem solved

Functional benefit

Products and services

  • Accelmed Fund I, LP
  • Accelmed Fund II, LP
  • Accelmed Ventures
  • Control and Growth Capital Investments

Quantifiable outcome

  • 26.4% net IRR for Fund I (top quartile performance)
  • +4 more outcomes

Companies that use Accelmed

Customer profile

Named customers8 records

Segments3 records

Ideal customer profiles2 records

Accelmed technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Accelmed partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Boehringer IngelheimcoreStrategic or Co-development Partner · 9 April 2026Pharmaceutical partner in Click Therapeutics' prescription digital therapeutic CT-155 for schizophrenia. Boehringer made $50M Series D strategic investment and transferred commercialization rights to Click. Ongoing collaboration on ENSPIRUS study completion.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Accelmed competitors and assessment

Company assessment

Direct peers

  • H.I.G. BioHealth Partners: Healthcare-focused PE firm with ~$400M committed capital that co-led Accelmed's investment in Click Therapeutics. Directly comparable as a HealthTech-dedicated growth equity and buyout sponsor operating in similar deal-size band.
  • Lauxera Capital Partners: HealthTech-focused investment firm based in Paris and San Francisco with a €260M vehicle that co-invested with Accelmed in Veranex. Closely comparable as a transatlantic HealthTech PE sponsor with similar sector focus.
  • Longitude Capital: Healthcare-dedicated growth equity firm investing in commercial-stage medical device, biotech, and digital health companies. Comparable to Accelmed in sector focus, stage (commercial/growth), and transaction sizes.
  • Patient Square Capital: Healthcare-focused PE firm making control and growth investments across medical devices, services, and pharmaceuticals. Comparable as a HealthTech-dedicated sponsor with a buy-and-build orientation similar to Accelmed.
  • Avista Capital Partners: Healthcare-focused PE firm investing in middle-market medical device, pharmaceutical, and healthcare services companies. Comparable to Accelmed in sector specialization and middle-market deal-size focus.
  • Linden Capital Partners: Healthcare-dedicated PE firm investing in middle-market companies across medical devices, specialty pharma, and services. Comparable to Accelmed in sector focus and lower middle market deal profile.
  • Sofinnova Partners: European healthcare and life sciences specialist with growth and venture capital strategies. Comparable to Accelmed in HealthTech sector focus though typically investing at earlier stages and primarily in European assets.
  • TVM Capital Healthcare: Healthcare-dedicated growth equity firm with US and Middle East operations. Comparable to Accelmed in healthcare specialization and growth-stage focus, with complementary geographic reach.
  • Ampersand Capital Partners: Middle-market PE firm specializing in healthcare and life sciences. Comparable to Accelmed in healthcare-dedicated middle-market deal profile and growth equity orientation.

Regional players

  • Gilde Healthcare: European healthcare specialist investing across medical devices, digital health, and therapeutics. Comparable to Accelmed in healthcare specialization but primarily serves European companies rather than the US lower middle market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Accelmed social profiles

Digital presence

Accelmed financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Accelmed leadership team

Management profile

Number of profiles

Profiles11 records

Accelmed funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Accelmed M&A and investment

M&A and investment

M&A4 records

Investments45 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Accelmed

What does Accelmed do?

Accelmed is a private equity firm that makes control and growth investments in U.S. commercial-stage lower middle market HealthTech companies with revenues of $20-70M (control) or $10M+ (growth). The firm manages over $630 million across two private equity funds (Fund I at $130M and Fund II at $400M) plus the earlier $100M Accelmed Ventures vehicle, deploying $20-100M+ per company in medical devices, diagnostics, digital health, and tech-enabled services, and working closely with management teams on operational improvements and buy-and-build strategies.

Is Accelmed a public or private company?

Accelmed is a private company. It is classified as venture growth investor backed and is currently operating.

When was Accelmed founded?

Accelmed was founded in 2009. It employs 1 to 10 people.

Where is Accelmed based?

Accelmed is headquartered in Miami, United States, in the North America region.

How does Accelmed make money?

Two revenue lines are on record. Management Fees are the primary driver. The others are carried Interest.

Who are Accelmed's main competitors?

Direct peers on record are H.I.G. BioHealth Partners, Lauxera Capital Partners, Longitude Capital, Patient Square Capital, Avista Capital Partners, Linden Capital Partners, Sofinnova Partners, TVM Capital Healthcare and Ampersand Capital Partners. Gilde Healthcare is listed as a regional player.

Does Accelmed have an API?

No public API is recorded for Accelmed.

What industry is Accelmed in?

Accelmed's product category is Healthcare Private Equity. Its primary akta.pro industry code is FSANACAL, Education / EdTech Growth Equity. Its NAICS code is 523940 and its SIC code is 8742.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageArticles from Bioventus, Inc.Bioventus Inc. announced a definitive agreement to sell its Advanced Rehabilitation business, including subsidiary Bioness, to private equity firm Accelmed Partners for $45 million in total consideration. The company also completed the prior divestiture of its Wound business to LifeNet Health in May 2023 for approximately $30 million in net proceeds. Both transactions are intended to allow Bioventus to focus on core operations and repay existing debt.BriefglanceBioness Acquires PoNS, Uniting Brain and Body RehabilitationBioness Medical, Inc. announced on April 9, 2026 the acquisition of the Portable Neuromodulation Stimulator (PoNS®) System from Helius Medical Technologies, a company that had been exploring strategic alternatives including a potential sale since November 2024. The deal combines Bioness's established peripheral functional electrical stimulation (FES) platform with PoNS's central brain stimulation technology, creating a dual-front neuromodulation approach for treating complex neurological conditions. The acquisition is the third under Accelmed Partners' ownership and is designed to transform Bioness into a comprehensive neurorehabilitation platform competing in a market projected to exceed $5 billion by 2032.Private Equity InsightsAccelmed Partners raises $400m to invest in commercial stage healthtech – Private Equity InsightsAccelmed Partners has closed its second fund, Accelmed Fund II, at its hard cap of $400 million, surpassing the initial target of $300 million. The fund is aimed at investing in US lower middle market HealthTech companies, focusing on medical devices, diagnostics, digital health, and technology-enabled healthcare services. This initiative reflects an increasing demand for technology-driven healthcare solutions and aims to support companies poised for growth amid a changing healthcare landscape.GlobeNewswireViscosupplementation Market Competitive Landscape Report 2025: Recent Developments, Company Strategies, Sustainability Benchmarking, Product Launches, Key Persons, and Revenue ForecastsThe viscosupplementation market is projected to grow from US$4.66 billion in 2024 to US$10.16 billion by 2033, representing a compound annual growth rate of 9.02%, driven by increasing demand for minimally invasive osteoarthritis treatments that inject hyaluronic acid derivatives into knee joints. Recent market developments include Anika Therapeutics' sale of Parcus Medical to Medacta Group in March 2025 and Bioventus' sale of its Advanced Rehabilitation division to Accelmed Partners for $45 million in October 2024. Zimmer Biomet launched its VISCO3 three-injection hyaluronate treatment in January 2024, reporting positive clinical outcomes including a 52% pain reduction at 12 weeks and relief lasting up to six months.FinSMEsCorvia Medical Raises $55M in FundingCorvia Medical raised $55M from Third Rock Ventures, General Catalyst, AccelMed, and others. The funds will complete the RESPONDER-HF trial of its Atrial Shunt device at over 65 institutions. The company aims to reduce left atrial pressure and improve heart failure outcomes.NewswireAcclaro Medical Raises $23 Million in Series B Funding Led by Accelmed Partners to Advance Groundbreaking 2910 nm Fiber Laser TechnologyAcclaro Medical raised $23 million in Series B funding led by Accelmed Partners with 3E Bioventures. The capital will accelerate its UltraClear and AuraLux fiber lasers and global expansion. The company aims to expand its team and reach more customers worldwide.PR NewswireAcclaro Medical Raises $23 Million in Series B Funding Led by Accelmed Partners to Advance Groundbreaking 2910 nm Fiber Laser TechnologyAcclaro Medical raised $23 million in Series B funding led by Accelmed Partners with 3E Bioventures. The capital will accelerate its 2910 nm fiber laser products UltraClear and AuraLux, and support global expansion. The company aims to expand its team and reach more customers worldwide.YahooAcclaro Medical Raises $23 Million in Series B Funding Led by Accelmed Partners to Advance Groundbreaking 2910 nm Fiber Laser TechnologyAcclaro Medical raised $23 million in Series B funding led by Accelmed Partners. The funds will support its 2910 nm fiber laser technology and strategic plans. The company aims to revolutionize the aesthetic industry with its proprietary skin rejuvenation treatments.MassDeviceGT Medical raises $37M to advance bioresorbable radiation tileGT Medical Technologies completed a $37 million first close of its Series D financing round to support clinical studies and commercialization of its GammaTile bioresorbable radiation implant. The funding, led by Evidity Health Capital with participation from Accelmed Partners and existing investors, will specifically advance the ROADS and GESTALT clinical trials for brain metastases and glioblastomas.PR NewswireGT Medical Technologies Raises $37 Million in Series D to Advance the Expansion of GammaTile® in the U.S. for Patients with Operable Brain TumorsGT Medical Technologies announced the completion of a $37 million first close for its Series D financing round, led by Evidity Health Capital with participation from Accelmed Partners and existing investors. The funds will accelerate the ROADS and GESTALT clinical studies for GammaTile while supporting the commercialization of the FDA-cleared bioresorbable radiotherapy implant. GT MedTech anticipates completing a second close of the round in Q1 2025 to expand clinical and commercial operations.